The ETF is rated as a 'Buy' by Zacks with low expense ratio (0.35%), strong year-to-date and one-year returns (21.89% and 39.46% respectively), and transparent holdings. However, positive sentiment is tempered by concentrated exposure and higher risk profile.
Recommended as the better buy despite lower 5-year returns; praised for lower expense ratio (0.35%), recent strong performance, and concentrated exposure to biotech leaders like Amgen and Gilead Sciences.
Acknowledged as a viable option with strong recent 3-year performance (9.1% annualized) and year-to-date gains (8.6%), but carries higher risk due to concentrated holdings (24 stocks), higher expense ratio (0.35%), and significantly larger maximum drawdown (39.9%), making it less suitable for long-term investors.
BBH underperforms VHT across multiple metrics: higher expense ratio (0.35%), lower dividend yield (0.5%), weaker 5-year returns, higher volatility (beta 0.68), and significantly larger maximum drawdown (39.9%). Suitable only for aggressive investors willing to accept higher risk and fees.
Offers strong short-term performance (30.8% 1-year return) and better 3-year returns (9.8%), but carries significant drawbacks including high volatility (39.9% maximum drawdown), concentrated portfolio (25 holdings), U.S.-only exposure, and weaker long-term 5-year performance (0.6% annualized).
BBH offers concentrated exposure to 25 biotech leaders but experienced higher volatility (beta 0.58, max drawdown -39.86%) and lower 1-year returns (33.30%) compared to XPH. Suitable for investors comfortable with concentration risk.
Articles that tag BBH but are mainly about other companies.
Provides exposure to 25 companies in genetic analysis and diagnostic equipment; surged 23.8% year-to-date with Zacks ETF Rank #2 (Buy).
Less favorable for most investors due to higher expense ratio (0.35%), lower dividend yield (0.4%), underperformance over 5 years, concentrated 25-stock portfolio carrying elevated single-company risk, and higher fees that don't provide compensating benefits.
Mentioned as significant ETF exposure holder but no specific performance impact or commentary provided in the article.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology